Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure infection

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1286-1297

  Augusto, Marcelo T ^a   Hollmann, Axel ^a   Castanho, Miguel A R B ^a   Porotto, Matteo ^b   Pessi, Antonello ^c   Santos, Nuno C ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PeptiPharma   (Italy)

Author keywords

Blood cells; Cholesterol tagging; Drug design; HIV 1

Indexed keywords

DIMERIC C34 CHOLESTEROL TAGGED INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MONOMERIC C34 CHOLESTEROL TAGGED INHIBITOR; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 41; PEPTIDE C34; PEPTIDE FRAGMENT; PROTEIN BINDING;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CELL MEMBRANE; DIPOLE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ERYTHROCYTE; FLUORESCENCE; HUMAN; HUMAN CELL; LIPID MEMBRANE; LIPID MONOLAYER; LIPID RAFT; LIPID VESICLE; MEMBRANE; MEMBRANE MODEL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; METABOLISM; MONONUCLEAR CELL;

CELL MEMBRANE; ERYTHROCYTES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 84898421928     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt529     Document Type: Article

References (48)

1. Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
2. Coffin J, Haase A, Levy J et al. Human immunodeficiency viruses. Science 1986; 232: 697-697.
3. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33: 307-20.
4. Steffen I, Pöhlmann S. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des 2010; 16: 1143-58.
5. He Y. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. Curr Pharm Des 2013; 19: 1800-9.
6. Montero M, van Houten NE, Wang X et al. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008; 72: 54-84.
7. Doms R, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000; 14: 2677-88.
8. Frey G, Peng H, Rits-Volloch S et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 2008; 105: 3739-44.
9. Chan DC, Fass D, Berger JM et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-73.
10. Tilton JC, DomsRW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010; 85: 91-100.
11. Robertson D. US FDA approves new class of HIV therapeutics. Nat Biotechnol 2003; 21: 470-1.
12. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30: 1228-50.
13. Trottier B, Walmsley S, Reynes J et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40: 413-21.
14. Franquelim HG, Chiantia S, Veiga AS et al. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes. AIDS 2011; 25: 419-28.
15. Veiga AS, Santos NC, Loura LMS et al. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc 2004; 126: 14758-63.
16. Franquelim HG, Loura LMS, Santos NC et al. Sifuvirtide screens rigid membrane surfaces. Establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J Am Chem Soc 2008; 130: 6215-23.
17. Matos PM, Castanho MARB, Santos NC. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS One 2010; 5: e9830.
18. Veiga AS, Henriques S, Santos NC et al. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J 2004; 377: 107-10.
19. Harman S, Herrera C, Armanasco N et al. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother 2012; 56: 2347-56.
20. Hollmann A, Matos PM, Augusto MTet al. Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. PLoS One 2013; 8: e60302.
21. Ingallinella P, Bianchi E, Ladwa NA et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA 2009; 106: 5801-6.
22. Pessi A, Langella A, Capito' E et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One 2012; 7: e36833.
23. Nomura W, Hashimoto C, Suzuki T et al. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors. Bioorg Med Chem 2013; 21: 4452-8.
24. NomuraW, Hashimoto C, Ohya A et al. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency. Chem Med Chem 2012; 7: 205-8.
25. Welch BD, VanDemark AP, Heroux A et al. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA 2007; 104: 16828-33.
26. Welch BD, Francis JN, Redman JS et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol 2010; 84: 11235-44.
27. Keeffe JR, Gnanapragasam PNP, Gillespie SK et al. Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proc Natl Acad Sci USA 2011; 108: 14079-84.
28. Szoka F, Olson F, Heath T et al. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 1980; 601: 559-71.
29. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858: 161-8.
30. Kubista M, Sjöback R, Eriksson S et al. Experimental correction for the inner-filter effect in fluorescence spectra. Analyst 1994; 119: 417.
31. Ladokhin AS, Jayasinghe S, White SH. How to measure and analyze tryptophan fluorescence in membranes properly, and why bother? Anal Biochem 2000; 285: 235-45.
32. Marquardt DW. An algorithm for least-squares estimation of nonlinear parameters. J Soc Ind Appl Math 1963; 11: 431-441
33. Santos NC, Prieto M, Castanho MARB. Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods. Biochim Biophys Acta 2003; 1612: 123-35.
34. Chiu SW, Subramaniam S, Jakobsson E. Simulation study of a gramicidin/lipid bilayer system in excess water and lipid. II. Rates and mechanisms of water transport. Biophys J 1999; 76: 1939-50.
35. Greenwood AI, Tristram-Nagle S, Nagle JF. Partial molecular volumes of lipids and cholesterol. Chem Phys Lipids 2006; 143: 1-10.
36. Jiang D, Dinh KL, Ruthenburg TC et al. A kinetic model for b-amyloid adsorption at the air/solution interface and its implication to the b-amyloid aggregation process. J Phys Chem B 2009; 113: 3160-8.
37. Yamazaki M, Miyazu M, Asano T et al. Direct evidence of induction of interdigitated gel structure in large unilamellar vesicles of dipalmitoylphosphatidylcholine by ethanol: studies by excimer method and high-resolution electron cryomicroscopy. Biophys J 1994; 66: 729-33.
38. Santos NC, Prieto M, Castanho MARB. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. Biochemistry 1998; 37: 8674-82.
39. Nagle JF, Wiener MC. Structure of fully hydrated bilayer dispersions. Biochim Biophys Acta 1988; 942: 1-10.
40. Matos PM, Freitas T, Castanho MARB et al. The role of blood cell membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide. Biochem Biophys Res Commun 2010; 403: 270-4.
41. Gross E, Bedlack RS, Loew LM. Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential. Biophys J 1994; 67: 208-16.
42. Clarke RJ, Kane DJ. Optical detection of membrane dipole potential: avoidance of fluidity and dye-induced effects. Biochim Biophys Acta 1997; 1323: 223-39.
43. Cladera J, O'Shea P. Intramembrane molecular dipoles affect the membrane insertion and folding of a model amphiphilic peptide. Biophys J 1998; 74: 2434-42.
44. Fernandes MX, García de la Torre J, Castanho MARB. Joint determination by Brownian dynamics and fluorescence quenching of the in-depth location profile of biomolecules in membranes. Anal Biochem 2002; 307: 1-12.
45. Veatch SL, Keller SL. A closer look at the canonical "Raft Mixture" in model membrane studies. Biophys J 2003; 84: 725-6. 46 Porotto M, Rockx B, Yokoyama CC et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 2010; 6: e1001168.
46. Porotto M, Rockx B, Yokoyama CC et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 2010; 6: e1001168.
47. De Almeida RFM, Fedorov A, Prieto M. Sphingomyelin/ phosphatidylcholine/cholesterol phase diagram: boundaries and composition of lipid rafts. Biophys J 2003; 85: 2406-16.
48. Haldar S, Kanaparthi RK, Samanta A et al. Differential effect of cholesterol and its biosynthetic precursors on membrane dipole potential. Biophys J 2012; 102: 1561-9.